Tyra Biosciences, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Nextech VI Oncology SCSp and related entities have reported beneficial ownership of 6.0% of Tyra Biosciences, Inc. common stock as of June 30, 2026.
NASDAQ
Farallon Capital Management and affiliated entities have filed a Schedule 13G, reporting a passive ownership stake in Tyra Biosciences, Inc.
NASDAQ
Commodore Capital LP and its principals have filed a Schedule 13G reporting a 4.2% beneficial ownership stake in Tyra Biosciences, Inc.
NASDAQ
Janus Henderson Group plc has reported beneficial ownership of 3,890,589 shares, representing 7.2% of the common stock of Tyra Biosciences, Inc., as of March 31, 2026.
NASDAQ
Todd Harris has disclosed beneficial ownership of 2,913,342 shares, representing 4.8% of Tyra Biosciences, Inc. common stock as of March 31, 2026.
NASDAQ
Farallon Capital Management, through various affiliated entities, has reported a beneficial ownership of 6.6% of Tyra Biosciences, Inc. common stock as of March 31, 2026.
NASDAQ
Canaan Partners entities have updated their beneficial ownership in Tyra Biosciences, reporting a reduction in holdings to 1.4% of outstanding shares.
NASDAQ
FMR LLC, through its affiliates, has reported beneficial ownership of 14.4% of Tyra Biosciences Inc.'s common stock as of March 31, 2026.
NASDAQ
Farallon Capital and its affiliates have disclosed a collective beneficial ownership of 5.6% in Tyra Biosciences, Inc. common stock.
NASDAQ
Canaan XI L.P. and its general partner, Canaan Partners XI LLC, reported beneficial ownership of 5.5% of Tyra Biosciences, Inc. common stock as of December 31, 2025.
NASDAQ
SCHEDULE 13G/A: Commodore Capital Discloses 6.3% Stake in Tyra Biosciences
Commodore Capital LP and its affiliates have reported a 6.3% beneficial ownership stake in Tyra Biosciences, Inc., totaling 3,375,000 shares of common stock.
NASDAQ
Vestal Point Capital and Ryan Wilder have filed an amendment to their Schedule 13G, reporting a reduced beneficial ownership of 4.5% in Tyra Biosciences, Inc. as of September 30, 2025.
NASDAQ
Janus Henderson Group plc has disclosed a 5.4% beneficial ownership stake in TYRA Biosciences, Inc., holding 2,856,290 common shares as of June 30, 2025.
NASDAQ
Vestal Point Capital, LP and Ryan Wilder have disclosed a passive 5.4% beneficial ownership stake in Tyra Biosciences, Inc., holding 2,879,829 shares of common stock.
NASDAQ
Commodore Capital LP and Commodore Capital Master LP have jointly reported a 5.2% beneficial ownership stake in Tyra Biosciences, Inc., holding 2,750,000 shares of common stock.
NASDAQ
Janus Henderson Group plc has filed a Schedule 13G, reporting a 5.1% beneficial ownership stake in TYRA Biosciences, Inc. as of March 31, 2025, held for investment purposes.
NASDAQ
SCHEDULE 13G/A: FMR LLC Reduces Stake in TYRA Biosciences Below 5% Threshold
FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, disclosing a reduced beneficial ownership of 3.2% in TYRA Biosciences Inc. as of March 31, 2025.
NASDAQ
TCG Crossover Fund I, L.P., TCG Crossover GP I, LLC, and Chen Yu have jointly disclosed a beneficial ownership of 5.7% in Tyra Biosciences, Inc., totaling 2,898,103 shares of common stock.
NASDAQ
SCHEDULE 13G/A: Biotechnology Value Fund Entities Disclose Significant 7.8% Stake in Tyra Biosciences
Multiple entities associated with Biotechnology Value Fund, including Mark N. Lampert, have disclosed a combined beneficial ownership of 7.8% in Tyra Biosciences, Inc. as of December 31, 2024.
NASDAQ
Canaan XI L.P. and its affiliated entities have filed an amended Schedule 13G, reporting a combined beneficial ownership of Tyra Biosciences, Inc. common stock as of December 31, 2024.